A large epidemiological study of more than 600,000 veterans with diabetes suggests GLP-1 weight-loss medications may reduce ...

A new study finds that popular GLP-1 drugs used to treat diabetes and obesity show new promise in fighting multiple substance use disorders.

The FDA issued warning letters to 30 telehealth companies over misleading claims about compounded versions of popular ...

New research suggests the weight-loss medications could be powerful tools in tackling substance use disorders.

A doctor sits with Tram Mai to discuss what we should know about GLP-1 drugs and their side effects. McDonald's CEO prepares ...

The FDA is taking no prisoners as it continues its efforts to combat widespread GLP-1 drug compounding. | In the letters sent ...

Ozempic, Mounjaro and other GLP-1 drugs for diabetes can prevent the formation of new substance ​use disorders and alleviate ...

People taking GLP-1 drugs often talk about “food noise” vanishing: the constant mental chatter about food that dominated thei ...

A new survey suggests about three million Canadian adults are currently taking GLP-1 drugs such as Ozempic or Mounjaro and ...

Researchers at Washington University School of Medicine in St. Louis have shown in a new study that GLP-1 medications may be ...

GLP-1 drugs Ozempic, Wegovy, Mounjaro and Zepbound can help patients lose anywhere from 15% to 20% of body weight. But what ...

People on GLP-1s had slightly higher risks of osteoporosis and gout than similar people not taking these drugs. But diet and ...